To buy shares in Recursion Pharmaceuticals Inc. Class A you will need a US based stock trading platform like Interactive Brokers or Moomoo where it currently costs $3.62 to buy one share in Recursion Pharmaceuticals Inc. Class A (as of 10:10 04-Jun-2026). Which is a change of $0.14 or 7.64% from the last closing price of $3.47.
How To Buy Recursion Pharmaceuticals Inc. Class A Stock
It may seem complicated to buy stock for the first time, but it’s actually very easy. Follow these simple steps to buy shares in Recursion Pharmaceuticals Inc. Class A:
- Pick a stock broker (jump down to compare the best brokers for buying Recursion Pharmaceuticals Inc. Class A stock)
- Deposit funds (bank transfer, ACH, wire transfer, or card)
- Search for the stock symbol: (NASDAQ:RXRX)
- Choose the number of shares you want to buy (1 share currently costs $3.62)
- Click buy (you can either trade immediately at “market” or set a “limit” to buy the stock cheaper if you think the price will go down)
- Track the performance of your Recursion Pharmaceuticals Inc. Class A stock in your account (this will show your profit and loss)
- Recursion Pharmaceuticals Inc. Class A is currently worth $1,896,530,350 based on the last closing price of $3.47 with 2,858,640 shares traded.
- The most recent Recursion Pharmaceuticals Inc. Class A daily high has been $3.71 and daily low $3.44.
- The Recursion Pharmaceuticals Inc. Class A stock price 52 week high has been $7.18 and the 52 week low $2.77.
Compare Brokers For Buying Recursion Pharmaceuticals Inc. Class A Stock
Is Now A Good Time To Buy Recursion Pharmaceuticals Inc. Class A Stock?
- Recursion Pharmaceuticals Inc. Class A’s EPS (earnings per share) are -1.2. A high EPS indicates strong profitability but may already be priced in, while a low EPS could signal weak earnings or a turnaround opportunity, requiring industry comparison.
- Recursion Pharmaceuticals Inc. Class A’s PE (price earnings ratio) is n/a. A low PE ratio may suggest undervaluation but could also indicate slow growth or risk, whereas a high PE ratio reflects high growth expectations but may signal overvaluation, necessitating a check on earnings sustainability.
The below Recursion Pharmaceuticals Inc. Class A share price analysis and market data includes key financials, earnings estimates, peer performance, dividends, news and a company profile that will give you an indication as to whether this stock is a buy, sell or hold. Subscribe to Good Money Guide Analysis for expert opinion on the latest investment opportunities.







